Comprehensive Guide to Local Anesthetics in Veterinary Medicine

Historical Development of Local Anesthetics

  • Botanical Origins:
    • Erythroxylum coca was cultivated in South and Central America prior to the arrival of Christopher Columbus.
    • Indigenous peoples chewed coca leaves to alleviate hunger, fatigue, thirst, and physical pain.

Erythroxylum coca plant displaying leaves and red berries

  • Chronological Milestones:
    • 1860: Albert Niemann isolated the active alkaloid from Erythroxylum coca, named it cocaine, and documented that it produced a distinct numbing sensation on the tongue.
    • 1880: Vassily von Anrep performed subcutaneous injections of cocaine into animals and into himself, subsequently recommending its adoption as a surgical local anesthetic.
    • July 1884: Sigmund Freud published his comprehensive cocaine review (Über Coca), identifying mucosal numbing properties without developing its surgical application.
    • September 11, 1884: Carl Koller performed the first clinical surgical procedure under local anesthesia, instilling cocaine topically into the eye of a glaucoma patient.
    • September 15–16, 1884: Dr. Josef Brettauer read Carl Koller's research paper at the Heidelberg Ophthalmology Congress on Koller's behalf.
    • October 11, 1884: Dr. Noyes reported Koller's ophthalmologic findings in the New York Medical Record.
    • October 17 & 25, 1884: Koller formally presented his findings to the Medical Society of Vienna and published them in the Wiener Medizinische Wochenschrift.
    • December 6, 1884: Koller's paper appeared in English in The Lancet.
    • 1884: Richard John Hall reported the first dental nerve block (Nash's infraorbital nerve block).
    • 1884: William Stewart Halsted introduced the inferior alveolar nerve block utilizing cocaine.
    • 1884–1891: Over 200 cases of severe systemic cocaine intoxication and 13 documented fatalities were reported worldwide; severe addiction emerged among early medical pioneers, including Sigmund Freud and William Halsted.
    • 1892: Carl Ludwig Schleich published methods for infiltration anesthesia using diluted cocaine solutions (0.1%−0.2%0.1\% - 0.2\%); François-Franck coined the term "regional block".
    • 1905: Heinrich Braun synthesized and introduced novocaine (procaine), demonstrating enhanced duration and safety when combined with adrenaline (epinephrine).
    • 1943–1946: Nils Löfgren and Bengt Lundquist synthesized lidocaine, the first clinically successful amino-amide local anesthetic.
    • 1957: Bo af Ekenstam and colleagues synthesized mepivacaine and bupivacaine.
    • 1969: Nils Löfgren and Bertil Tegner synthesized prilocaine.
    • 1972: Adams and colleagues developed etidocaine; the first scientific article on articaine was published.
    • 1980: Synthesis and clinical development of ropivacaine, a single S(−)S(-) enantiomer.

General Principles and Clinical Rationale

  • Mechanism of Action Definition:
    • Local anesthetics reversibly block the generation and propagation of electrical impulses in excitable nerve fibers, producing complete sensory desensitization and motor blockade within a targeted anatomical region.
  • Clinical Benefits of Regional Anesthesia:
    • Improvement of Recovery Quality: Provides targeted preemptive and postoperative analgesia, facilitating smoother emergence and reducing agitation.
    • Decrease in General Anesthetic Requirements: Produces substantial minimal alveolar concentration (MAC) sparing effects on volatile inhalants, lowering reliance on heavy systemic central depressants.
    • Reduction in Patient Mortality: Mitigates intraoperative surgical stress responses, hemodynamic fluctuations, and systemic opioid/sedative burdens.
    • Mainstay Analgesic Modality: Forms the foundation of modern multimodal local and regional analgesic protocols across veterinary and human clinical medicine.

Anatomy and Physiology of the Voltage-Gated Sodium Channel

  • Channel Architecture:
    • The functional voltage-gated sodium (Na+\text{Na}^+) channel (e.g., NaV1.8\text{Na}_\text{V}1.8) is a heterotrimeric glycoprotein complex embedded in excitable membranes.
    • Composed of a massive central pore-forming α\alpha subunit (∼260 kDa\sim 260\,\text{kDa}) associated with two auxiliary regulatory β\beta subunits.
    • The α\alpha subunit comprises four homologous domains (designated Domains I, II, III, and IV).
    • Each homologous domain contains six transmembrane ̔\alpha-helical segments (designated S1 through S6).
    • Segment 4 (S4) contains repeating positively charged amino acid residues (arginine and lysine) and functions as the primary voltage sensor of the channel.
    • Inward movement or outward rotation of S4 in response to transmembrane potential fluctuations triggers opening or closing of the pore.
    • An intracellular peptide loop between Domain III and Domain IV serves as the hinged inactivation gate.

Conformations of the voltage-gated sodium channel

  • Conformational States:
    • The Na+\text{Na}^+ channel cycles through three distinct functional states during an action potential:
    1. Resting-Closed State: Occurs at normal resting negative membrane potentials (∼−70 mV\sim -70\,\text{mV}); the activation gate is shut and the inactivation gate is open.
    2. Activated-Open State: Membrane depolarization induces conformational shift in the S4 voltage sensors, opening the activation pore to allow rapid inward diffusion of Na+\text{Na}^+ along its electrochemical gradient.
    3. Inactivated-Closed State: Within 1−2 ms1 - 2\,\text{ms} of channel opening, the intracellular hinged inactivation gate swings shut into the inner pore mouth, terminating Na+\text{Na}^+ influx and initiating repolarization (K+\text{K}^+ efflux). Repolarization resets the channel back to the resting-closed conformation within 2−5 ms2 - 5\,\text{ms} (the refractory period).

Chemical Structure and Classification

  • Three Basic Structural Moieties:
    1. Lipophilic Aromatic Group: A substituted benzene ring providing essential lipid solubility, enabling membrane penetration.
    2. Intermediate Linkage Chain: An ester bond (−COO−-\text{COO}-) or an amide bond (−NH−CO−-\text{NH}-\text{CO}-) connecting the aromatic group to the amine group. This bond determines the chemical classification, metabolic pathway, and allergic potential of the molecule.
    3. Hydrophilic Amine Group: A tertiary or quaternary aliphatic amine containing ionizable nitrogen, conferring water solubility and existing in equilibrium between charged and uncharged states.

Chemical structure of local anesthetics showing aromatic group, intermediate linkage, and tertiary amine

  • Nomenclature and Structural Classification:

    • Amino-Esters (One "i" Rule): Compounds whose intermediate linkage is an ester chain. The generic spelling contains only one "i" before the "-caine" suffix (e.g., Procaine, Cocaine, Benzocaine, Tetracaine, Chloroprocaine, Proparacaine).
    • Amino-Amides (Two "i" Rule): Compounds whose intermediate linkage is an amide chain. The generic spelling contains two "i"s, with an "i" present in the prefix preceding the "-caine" suffix (e.g., Lidocaine, Bupivacaine, Mepivacaine, Ropivacaine, Levobupivacaine, Prilocaine, Etidocaine). Amino-amides represent the most common class utilized in modern veterinary medicine.
  • Physicochemical Dissociation Constants (pKa\text{p}K_a):

Generic Drug NameStructural ClassDissociation Constant (pKa\text{p}K_a)
CocaineAmino-Ester8.68.6
TropacocaineAmino-Ester9.39.3
BenzocaineAmino-Ester— (Permanently un-ionized at physiological pH)
ProcaineAmino-Ester8.98.9
TetracaineAmino-Ester8.58.5
2-chloroprocaineAmino-Ester8.78.7
DibucaineAmino-Ester8.88.8
LidocaineAmino-Amide7.6−7.87.6 - 7.8
MepivacaineAmino-Amide7.67.6
PrilocaineAmino-Amide7.97.9
BupivacaineAmino-Amide8.18.1
EtidocaineAmino-Amide7.77.7
RopivacaineAmino-Amide8.18.1
LevobupivacaineAmino-Amide8.18.1

Physicochemical Properties and Pharmacodynamics

  • Dissociation Constant (pKa\text{p}K_a) and Onset of Action:
    • Local anesthetics are weak bases formulated commercially as acidic hydrochloride salts (pH 4.0−6.0\text{pH}\ 4.0 - 6.0) to optimize stability and solubility.
    • In vivo dissociation is governed by the Henderson-Hasselbalch equation:

pH=pKa+log⁡([B][BH+])\text{pH} = \text{p}K_a + \log\left(\frac{[\text{B}]}{[\text{BH}^+]}\right)

log⁡([Base][Acid])=pH−pKa\log\left(\frac{[\text{Base}]}{[\text{Acid}]}\right) = \text{pH} - \text{p}K_a

  • Ionization Fraction: At normal physiological tissue pH (7.47.4), local anesthetics exist in equilibrium between the uncharged, lipophilic free base ([B][\text{B}]) and the positively charged, protonated hydrophilic conjugate acid ([BH+][\text{BH}^+]).

  • Most amino-amides have pKa\text{p}K_a values between 7.67.6 and 8.18.1. Because the pKa\text{p}K_a exceeds physiological pH, more than 50%50\% of the molecules exist in the ionized ([BH+][\text{BH}^+]) form.

  • Correlation with Onset:

    • A lower pKa\text{p}K_a closer to physiological pH (7.47.4) yields a greater fraction of un-ionized lipophilic base ([B][\text{B}]), allowing rapid diffusion through neural connective tissue sheaths and perineurium, leading to a faster onset of anesthesia.

    • Example: Lidocaine (pKa=7.7−7.8\text{p}K_a = 7.7 - 7.8) produces a [Base][Acid]\frac{[\text{Base}]}{[\text{Acid}]} ratio of approximately 0.40.4 at tissue pH 7.47.4, yielding a rapid onset time of 5 minutes5\,\text{minutes}.

    • A higher pKa\text{p}K_a yields greater ionization ([BH+][\text{BH}^+]) and less non-ionized base, slowing perineural diffusion and delaying onset.

    • Example: Bupivacaine (pKa=8.1\text{p}K_a = 8.1) exhibits an onset time of 20−30 minutes20 - 30\,\text{minutes}.

    • Acidic Environment and Inflamed/Infected Tissue:

  • Inflamed or infected tissue (such as an abscess or traumatized wound bed) has a reduced extracellular pH (pH 7.1\text{pH}\ 7.1 or lower, down to 4.0−6.04.0 - 6.0).

  • When environmental pH decreases relative to the drug's fixed pKa\text{p}K_a, the chemical equilibrium shifts heavily toward the protonated, ionized form ([BH+][\text{BH}^+]).

  • Because charged molecules cannot cross the hydrophobic lipid bilayers of cell membranes, neural uptake is impeded, resulting in delayed onset or complete clinical failure of the local block.

  • Concurrently, inflammation induces regional vasodilation and increased microvascular perfusion, which accelerates systemic clearance of the drug away from the target nerve, dropping effective local tissue concentrations.

Impact of tissue pH on local anesthetic penetration in healthy vs inflamed tissue

  • Lipid Solubility and Anesthetic Potency:
    • Intrinsic lipid solubility is the primary determinant of local anesthetic potency.
    • Highly lipid-soluble molecules (such as bupivacaine) readily dissolve in and traverse cell membranes, requiring fewer total extracellular drug molecules to achieve adequate blocking concentrations in the axoplasm.
    • Bupivacaine is approximately 4×4\times more potent than lidocaine.
  • Protein Binding and Duration of Effect:
    • Local anesthetics bind avidly to tissue proteins and circulating plasma proteins, primarily α1-acid glycoprotein\alpha_1\text{-acid glycoprotein}.
    • Protein binding directly correlates with duration of clinical anesthesia; agents with high affinity for membrane receptor proteins remain bound longer, resisting vascular wash-out.
    • Bupivacaine exhibits extremely high protein binding (∼95%\sim 95\%), granting a long duration of effect (3−10 hours3 - 10\,\text{hours}), whereas lidocaine exhibits lower protein binding (∼65%\sim 65\%) with a moderate duration (1−2 hours1 - 2\,\text{hours}).
  • Molecular Weight:
    • Most local anesthetic molecules range in molecular weight between 220220 and 288 Da288\,\text{Da}.
    • Smaller molecular weights allow faster radial diffusion through tissue interstitial spaces and the perineural sheath.

Molecular Mechanism of Action and Receptor Interaction

  • Axonal Membrane Penetration and Intracellular Ionization:
    • The lipophilic un-ionized base ([B][\text{B}]) crosses the axonal phospholipid bilayer via passive diffusion.
    • Once within the axoplasm, re-equilibration occurs based on intracellular pH (∼7.2\sim 7.2), and the base is protonated into the ionized conjugate acid ([BH+][\text{BH}^+]).
    • Receptor Interaction Rule: ONLY the ionized hydrophilic form ([BH+][\text{BH}^+]) binds to the inner receptor site inside the pore to block channel conductance. The un-ionized base cannot interact with the receptor site directly.
    • A minor alternate route involves direct entry of hydrophilic ionized molecules ([BH+][\text{BH}^+]) through the open external channel pore, but this pathway contributes minimally to clinical blockade.

Model of axonal membrane crossing and receptor blockade by ionized local anesthetic

  • Specific Receptor Binding Pocket:
    • The high-affinity local anesthetic receptor site resides within the inner pore vestibule on the cytoplasmic side of the α\alpha subunit.
    • The receptor site is localized within Domain IV, transmembrane segment 6 (IVS6), with contributions from Domain III segment 6 (IIIS6).
    • Critical Binding Residues (numbering based on rat brain NaV1.2\text{Na}_\text{V}1.2 isoform):
    • Phenylalanine at position 1764 (IVS6-Phe): Essential for high-affinity binding. Mutational deletion of this phenylalanine residue abolishes high-affinity local anesthetic block (corresponds to Phe-1579 in skeletal muscle NaV1.4\text{Na}_\text{V}1.4, and Phe-1759/Phe-1760 in cardiac NaV1.5\text{Na}_\text{V}1.5).
    • Tyrosine at position 1771 (IVS6-Tyr): Stabilizes the bound drug via hydrophobic and aromatic interactions.
    • Leucine at Domain III segment 6 (IIIS6-Leu): Contributes to hydrophobic wall lining of the vestibule.
    • DEKA Selectivity Filter (IIIP-Lys): Sits immediately extracellular to the drug-binding cavity.

Molecular model of lidocaine bound to IVS6-Phe and IVS6-Tyr within the sodium channel pore

  • State-Dependent and Frequency-Dependent Blockade:
    • Guarded-Receptor Hypothesis: The receptor is located within the internal pore vestibule; local anesthetic molecules gain physical access to this site only when channel gates open or inactivate.
    • Use-Dependent (Phasic) Block: Repetitive electrical stimulation increases channel cycling through open and inactivated states, accelerating drug entry and markedly enhancing the depth of blockade. Actively firing nociceptive fibers are blocked more rapidly than quiescent nerves.
    • Tonic Block: The steady-state, basal level of channel blockade achieved in unstimulated, resting nerves.
    • Secondary Molecular Targets: At elevated clinical doses, local anesthetics exhibit secondary low-affinity inhibitory actions on voltage-gated potassium (K+\text{K}^+) and calcium (Ca2+\text{Ca}^{2+}) channels.

Differential Nerve Blockade

  • Clinical Sequence of Blockade:

    • Local anesthetics produce a predictable functional loss that occurs in a cascading sequence:
    1. Vasodilation: Autonomic sympathetic B fibers and unmyelinated vasomotor C fibers are blocked first.
    2. Loss of Sensation: Temperature (cold before warm), sharp pain, dull burning pain, and light touch are eliminated progressively.
    3. Loss of Motor Function: Deep pressure, voluntary motor activity, and proprioception are lost last.
    • Clinically, patients retain motor function (e.g., maintaining the ability to voluntarily wiggle digits) while surgical analgesia is already complete.
  • Determinants of Differential Sensitivity:

    • Choice and concentration of local anesthetic drug.
    • Diameter of the nerve axon.
    • Degree of myelination.
    • Anatomical length of the nerve exposed to the drug solution (successful conduction block in myelinated axons requires exposure of at least three consecutive nodes of Ranvier, approximately 8−10 mm8 - 10\,\text{mm} of nerve length).
    • Frequency of electrical nerve stimulation.
  • Erlanger and Gasser Nerve Fiber Classification:

ClassificationDiameter (μm\mu\text{m})MyelinConduction Velocity (m/s\text{m/s})Anatomical LocationPhysiological FunctionSusceptibility / Order of Blockade
B<3< 3++ (light)3−153 - 15Preganglionic autonomic sympatheticAutonomic vasomotor efferents1 (Fastest / Most Sensitive)
Aδ\delta2−52 - 5++ (moderate)12−3012 - 30Afferent sensory nervesSharp, fast pain; cold temperature; light touch2
C0.4−1.20.4 - 1.2−- (unmyelinated)0.5−20.5 - 2Postganglionic sympathetic; dorsal root afferentsSlow, burning pain; warmth; autonomic postganglionic2
Aγ\gamma3−63 - 6++ (moderate)15−3015 - 30Efferent to muscle spindlesMuscle tone regulation3
Aβ\beta5−125 - 12++ (heavy)30−7030 - 70Afferent sensory; efferent to muscleDiscriminative touch; vibration; pressure; motor4
Aα\alpha12−2012 - 20++ (heavy)70−12070 - 120Afferent and efferent for somatic muscles/jointsSomatic motor efferents; proprioception5 (Slowest / Most Resistant)
  • Core vs. Mantle Architecture:
    • In large mixed peripheral nerve trunks, fibers innervating distal anatomical structures travel internally in the central "core", while proximal sensory fibers travel circumferentially in the outer "mantle".
    • Local anesthetics diffuse radially from outside to inside, blocking outer mantle sensory fibers first, while thicker, myelinated motor fibers situated deeply within the core are penetrated and blocked last.
    • Mnemonic for A-fiber blockade susceptibility: DGBA (Delta →\rightarrow Gamma →\rightarrow Beta →\rightarrow Alpha).

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

  • Systemic Absorption Determinants:
    • Vascularity of Injection Site: Follows a consistent hierarchy based on capillary blood flow:

Intercostal>Epidural>Brachial Plexus>Sciatic/Femoral\text{Intercostal} > \text{Epidural} > \text{Brachial Plexus} > \text{Sciatic/Femoral}

  • Highly vascular sites (intercostal spaces) lead to rapid systemic absorption, higher peak plasma drug concentrations (CmaxC_\text{max}), shorter duration of local block, and increased risk of systemic toxicity.
  • Intrinsic Vasoactivity: Most local anesthetics induce peripheral arteriolar vasodilation, promoting self-absorption into systemic circulation. Levobupivacaine and ropivacaine exhibit a biphasic response: producing vasoconstriction at low clinical concentrations and vasodilation at higher concentrations.
  • Lipid Solubility: Highly lipophilic drugs sequester extensively into local adipose and connective tissue matrices, slowing vascular clearance.
    • Pharmaceutical Additives and Formulations:
  • Epinephrine (1:200,0001:200,000 or 5 μg/mL5\,\mu\text{g/mL}): Stimulates local α1-adrenergic\alpha_1\text{-adrenergic} receptors, causing intense vasoconstriction. Decreases vascular absorption, reduces peak plasma levels, minimizes toxicity, and prolongs local duration of action.
  • Hyaluronidase: Hydrolyzes hyaluronic acid within tissue interstitial spaces, reducing interstitial viscosity and facilitating wider tissue penetration and drug spread.
  • Sodium Bicarbonate (NaHCO3\text{NaHCO}_3): Adding 1 mL1\,\text{mL} of 8.4%8.4\% sodium bicarbonate per 9−10 mL9 - 10\,\text{mL} of local anesthetic (e.g., lidocaine) alkalinizes the solution toward physiological pH, increasing the un-ionized lipid-soluble base fraction to accelerate onset and decrease the burning sting of acidic injections.
  • α2-Adrenergic Agonists\alpha_2\text{-Adrenergic Agonists}: Dexmedetomidine added to regional blocks prolongs the duration of analgesia via local vasoconstriction and direct neural hyperpolarization.
    • Distribution and Disposition:
  • Amino-amides bind circulating α1-acid glycoprotein\alpha_1\text{-acid glycoprotein} and serum albumin.
  • First-Pass Pulmonary Uptake: Lipophilic amides are rapidly extracted and temporarily buffered by pulmonary capillary beds during first-pass circulation, mitigating acute systemic arterial spikes.
  • Tissue Distribution: Highly distributed into vessel-rich organs, skeletal muscle, and secreted into milk. Clinicians consult the Food Animal Residue Avoidance Databank (FARAD) to establish mandatory withdrawal times for meat and milk in food-producing animals.
  • Placental Transfer and Ion Trapping: Amino-amides cross the placenta via passive diffusion. Because fetal mammalian blood has a lower physiological pH than maternal blood, un-ionized drug entering the fetal circulation becomes protonated into the ionized form ([BH+][\text{BH}^+]), which cannot cross back into maternal circulation, concentrating drug in the fetus.
    • Metabolism and Excretion:
  • Amino-Esters:
    • Rapidly hydrolyzed in plasma by pseudocholinesterase (butyrylcholinesterase) and nonspecific tissue esterases.
    • Extremely short elimination half-life (<1 minute< 1\,\text{minute} for chloroprocaine; few minutes for procaine).
    • Procaine and benzocaine are cleaved into para-aminobenzoic acid (PABA), a compound linked to hypersensitivity and allergic reactions.
    • Excreted primarily through the kidneys in urine.
  • Amino-Amides:
    • Exclusively metabolized by hepatic microsomal enzymes (Cytochrome P450 system) via N-dealkylation\text{N-dealkylation} and peptide hydroxylation.
    • Hepatic clearance hierarchy: Prilocaine >> Etidocaine >> Lidocaine >> Mepivacaine >> Ropivacaine >> Bupivacaine.
    • Excreted as polar hydrophilic metabolites in urine and secondarily via bile.

Profiles of Individual Amino-Ester Agents

  • Procaine (Novocaine):

    • Slow onset, short duration of action (30−60 minutes30 - 60\,\text{minutes}).
    • Rapidly hydrolyzed by plasma pseudocholinesterase with low intrinsic systemic toxicity.
    • Cleaved into PABA, which can trigger immune-mediated allergic reactions.
    • Acts as a central nervous system stimulant in equine patients.
    • Historically formulated as an insoluble repository vehicle with benzylpenicillin (Procaine Penicillin G); procaine residues can trigger drug testing disqualifications in racing horses.
  • Benzocaine:

    • Possesses an exceptionally low pKa\text{p}K_a (3.53.5), meaning it exists entirely in the un-ionized lipophilic form at physiological pH.
    • Virtually insoluble in water; formulated strictly for topical dermal and mucosal applications.
    • Clinical Hazard: Directly induces methemoglobinemia across domestic species (especially cats); contraindicated for general veterinary use.
    • Utilized as an immersion bath anesthetic in aquaculture and fish research (though tricaine is preferred).
  • Proparacaine:

    • Dedicated exclusively to topical corneal and ophthalmic anesthesia (0.5%0.5\% solution).
    • Rapid onset of ocular anesthesia within 1 minute1\,\text{minute}; short clinical duration of 15−25 minutes15 - 25\,\text{minutes}.
    • Minimizes corneal sensation during tonometry, corneal cytology, and ocular foreign body removal.
    • Causes temporary, transient inhibition of normal lacrimal production (tear flow).
  • Tetracaine:

    • High potency, long-acting amino-ester used primarily in topical ophthalmic preparations and spinal formulations.
  • Tricaine Methanesulfonate (MS-222):

    • Water-soluble amino-ester formulated for immersion anesthesia in teleost fish, elasmobranchs, and amphibians.

Profiles of Individual Amino-Amide Agents

  • Lidocaine (Lignocaine):

    • The gold-standard, most ubiquitous local anesthetic in veterinary practice.
    • Pharmacodynamics: Rapid onset (5−10 minutes5 - 10\,\text{minutes}); moderate duration of sensory anesthesia (1−2 hours1 - 2\,\text{hours}), which can be prolonged up to 3−4 hours3 - 4\,\text{hours} with epinephrine (1:200,0001:200,000).
    • Formulations: Available as 0.5%0.5\%, 1.0%1.0\%, 1.5%1.5\%, and 2.0%2.0\% solutions.
    • Routes of Administration: Local tissue infiltration, peripheral nerve block, epidural, intrathecal (spinal), topical, and intravenous infusion.
    • Topical Preparations: Dermal patches (5%5\% lidocaine patch) for localized neuropathic pain, and EMLA cream (a eutectic mixture of 2.5%2.5\% lidocaine and 2.5%2.5\% prilocaine) for transdermal analgesia prior to venipuncture.
    • Laryngeal Desensitization in Intubation:
    • Applied topically to arytenoid cartilages prior to endotracheal intubation in species prone to fatal laryngospasm (cats, pigs, sheep, goats, calves, South American camelids).
    • Feline Clinical Timing Guideline (Jones et al., 2021): Quantitative laryngeal reactivity scores demonstrate that the lowest spasm reactivity occurs precisely 45 seconds45\,\text{seconds} post-application of topical lidocaine. Anesthetists must wait at least 45 seconds45\,\text{seconds} before intubation to avoid inducing paradoxical vocal cord spasm; the patient should receive pre-oxygenation during this latency period.
    • Systemic (Intravenous) Non-Anesthetic Indications:
    • Class Ib Antiarrhythmic: Selective blocker of open and inactivated cardiac Na+\text{Na}^+ channels; used to control ventricular tachycardia and ventricular premature complexes (VPCs).
    • MAC Sparing: Continuous rate infusion (CRI) significantly reduces volatile inhalant anesthetic requirements by 15−40%15 - 40\% in dogs and horses.
    • Systemic Analgesia: Modulates central sensitization and suppresses ectopic somatic and visceral nociceptive firing.
    • Anti-Inflammatory Properties: Inhibits circulating neutrophil activation, superoxide free radical release, and inflammatory cytokine cascades.
    • Equine Prokinetic: Prevents or resolves postoperative ileus (POI) in horses undergoing gastrointestinal colic surgery by suppressing sympathetic tone and reducing inflammatory smooth muscle stasis.
    • Metabolism: Rapidly dealkylated in the liver into monoethylglycinexylidine (MEGX) and subsequently into glycinexylidine (GX). MEGX is pharmacologically active and contributes to neurotoxicity during prolonged infusions.
  • Mepivacaine (Carbocaine):

    • Exhibits similar potency and onset to lidocaine with a longer clinical duration (2−3 hours2 - 3\,\text{hours}).
    • Causes minimal intrinsic vasodilation, resulting in lower local tissue clearance without requiring vasoconstrictor additives.
    • Formulated as 0.5%0.5\% and 2.0%2.0\% solutions; not administered topically or intravenously.
    • Equine Indication: Preferred agent for diagnostic perineural and intra-articular lameness blocks in horses because it produces minimal local tissue edema, tissue reaction, or swelling.
  • Bupivacaine (Marcaine):

    • Highly lipophilic agent, approximately 4×4\times more potent than lidocaine.
    • Characterized by a slow onset (20−30 minutes20 - 30\,\text{minutes}) and a prolonged clinical duration (3−10 hours3 - 10\,\text{hours}).
    • Formulated at concentrations of 0.125%0.125\%, 0.25%0.25\%, 0.5%0.5\%, and 0.75%0.75\%.
    • Utilized for peripheral nerve blocks, wound infiltration, dental blocks, epidurals, and intrathecal blocks in small animals.
    • Contraindication: NEVER administered intravenously; exhibits severe, refractory cardiotoxicity.
  • Ropivacaine (Naropin):

    • Pure S(−)S(-) levorotatory enantiomer of a propyl-substituted homologue.
    • Demonstrates clinical onset (15−20 minutes15 - 20\,\text{minutes}) and duration (4−8 hours4 - 8\,\text{hours}) comparable to bupivacaine.
    • Produces significantly less central nervous system and myocardial toxicity than racemic bupivacaine.
    • Features greater separation between sensory and motor blockade, preserving motor function at low concentrations.
  • Levobupivacaine (Chirocaine):

    • The pure S(−)S(-) enantiomer of bupivacaine.
    • Possesses a clinical profile similar to bupivacaine, with a safer cardiovascular profile and less myocardial depression than racemic bupivacaine.
  • Liposomal Bupivacaine (NOCITA™):

    • Utilizes multivesicular liposome (MVL) DepoFoam technology consisting of microscopic spherical lipid bilayers arranged in a honeycomb configuration encapsulating internal aqueous pockets of bupivacaine (13.3 mg/mL13.3\,\text{mg/mL}).

DepoFoam multivesicular liposome structure encapsulating bupivacaine

  • Releases bupivacaine via gradual erosion and lipid breakdown, maintaining local tissue concentrations and providing continuous regional analgesia for up to 72 hours72\,\text{hours}.
  • Veterinary Approvals:
    • Surgical wound infiltration closure in dogs following cranial cruciate ligament surgery (such as Tibial Plateau Leveling Osteotomy / TPLO).
    • Peripheral nerve block tissue infiltration for feline onychectomy (declaw procedures).

Local Anesthetic Systemic Toxicity (LAST)

  • Etiology and Pathophysiology:

    • Caused by inadvertent direct intravascular administration, administration of absolute drug overdoses, or rapid tissue absorption from vascular injection sites.
    • Toxicity parallels intrinsic lipid solubility and anesthetic potency (Bupivacaine >>>> Lidocaine).
    • Patient physiological states such as systemic acidosis, hypercapnia, hypoxia, and hyperkalemia increase cardiac vulnerability and reduce seizure thresholds.
  • Biphasic Central Nervous System Toxicity (Precedes CV Signs):

    • Local anesthetics cross the blood-brain barrier rapidly.
    • Early / Low Toxicity: Selective inhibition of cortical inhibitory interneurons, leading to sedation, glazed demeanor, lightheadedness, and perioral/lingual paresthesias.
    • Moderate Toxicity: Unopposed excitatory pathway activity, resulting in muscle fasciculations, facial tremors, shivering, and generalized tonic-clonic seizures. Equine signs include rapid eye blinking, head shaking, mild sedation, and ataxia.
    • Severe / High Toxicity: Massive generalized central depression leading to profound stupor, coma, respiratory center arrest, and death.
  • Cardiovascular System Toxicity:

    • Direct blockade of cardiac voltage-gated Na+\text{Na}^+ channels (NaV1.5\text{Na}_\text{V}1.5) suppresses the Phase 0 upstroke velocity (VmaxV_\text{max}) of cardiac action potentials, impairing excitation, conduction velocity, and contractility.
    • Low Dose Effects: Sinus tachycardia, widening of the QRS complex, prolongation of the PR interval.
    • Moderate Dose Effects: Hyperactive sympathetic discharge, increased peripheral vascular resistance, systemic hypertension, supraventricular and ventricular arrhythmias.
    • High Dose Effects / Circulatory Collapse: Profound myocardial negative inotropy, extreme bradycardia, severe hypotension, high-grade atrioventricular block, refractory ventricular fibrillation, electromechanical dissociation, asystole, and death.
    • Bupivacaine Cardiotoxicity: Highly lipophilic; binds rapidly to open/inactivated cardiac Na+\text{Na}^+ channels but dissociates slowly during diastole ("fast in, slow out"), generating refractory ventricular arrhythmias.
  • Emergency Management and Resuscitation Protocol:

    1. Immediate Cessation: Stop local anesthetic injection or infusion instantly.
    2. Airway and Oxygenation: Secure the airway via cuffed endotracheal intubation; deliver 100%100\% oxygen with positive pressure ventilation to prevent hypoxia and hypercapnic acidosis.
    3. Seizure Management: Suppress motor seizures using intravenous benzodiazepines (midazolam or diazepam at 0.2−0.5 mg/kg0.2 - 0.5\,\text{mg/kg}) or low-dose propofol.
    4. Arrhythmia Therapy: Initiate standard cardiovascular life support. CRITICAL WARNING: DO NOT administer lidocaine or class I antiarrhythmics to treat local anesthetic-induced arrhythmias, as doing so worsens sodium channel toxicity.
    5. Intravenous Lipid Emulsion (ILE / Intralipid 20%20\%):
    • Primary pharmacological antidote for severe LAST, functioning via a "lipid sink" mechanism that extracts lipophilic local anesthetics from tissue membranes, along with providing metabolic and cardiotonic inotropic support.
    • Dosing: Administer an initial intravenous bolus of 1−4 mL/kg1 - 4\,\text{mL/kg} over 1−3 minutes1 - 3\,\text{minutes}, followed by a continuous rate infusion of 0.25 mL/kg/min0.25\,\text{mL/kg/min} until hemodynamic stability is restored.

Other Systemic and Local Adverse Effects

  • Methemoglobinemia:
    • Mechanism: Toxic oxidative metabolites of amino-ester benzocaine and amino-amide prilocaine oxidize the iron within hemoglobin from the normal ferrous state (Fe2+\text{Fe}^{2+}) to the ferric state (Fe3+\text{Fe}^{3+}), forming methemoglobin.
    • Methemoglobin cannot bind and transport molecular oxygen, shifting the oxygen-hemoglobin dissociation curve to the left and precipitating functional cellular hypoxia and metabolic acidosis.
    • Species Sensitivity: Feline patients are susceptible because feline hemoglobin contains eight sulfhydryl groups per molecule (compared to two in humans and four in canines), rendering it vulnerable to oxidative denaturation and precipitating Heinz body hemolytic anemia.
    • Clinical Presentation: Development of slate-grey, cyanotic, or brownish-blue mucous membranes, dark nasal planum, and cyanotic paw pads that fail to resolve upon delivery of 100%100\% inspired oxygen. Venous blood displays a characteristic "chocolate brown" appearance that does not turn red when exposed to room air.

Clinical cyanosis of mucous membranes and paw pads in a cat with methemoglobinemia

  • Treatment: Slow intravenous administration of Methylene Blue (1%1\% solution at 1−1.5 mg/kg1 - 1.5\,\text{mg/kg} IV), which acts as an electron donor to reduce ferric iron (Fe3+\text{Fe}^{3+}) back to ferrous iron (Fe2+\text{Fe}^{2+}).

    • Immunologic Hypersensitivity and Allergic Reactions:
  • True IgE-mediated anaphylaxis is exceedingly rare (<1%< 1\% of all adverse reactions).

  • Almost exclusively associated with amino-esters (procaine, benzocaine) because metabolic hydrolysis releases para-aminobenzoic acid (PABA), a potent allergenic hapten.

  • Amino-amides do not metabolize to PABA; documented allergic responses to amides are typically caused by added antimicrobial preservatives such as methylparaben.

    • Local Tissue Toxicities:
  • Neurotoxicity: Direct histological injury to neural axons and Schwann cells resulting from persistent chemical exposure to high concentrations of local anesthetics, or caused mechanically by high-pressure intraneural injection.

  • Myotoxicity: Dose-dependent skeletal muscle fiber necrosis (myonecrosis) occurs when local anesthetics are injected directly into muscle beds. The effect is typically reversible, with regeneration complete within 2−4 weeks2 - 4\,\text{weeks}.

  • Chondrotoxicity: Direct, irreversible dose- and exposure-dependent destruction of articular chondrocytes following intra-articular administration (especially continuous intra-articular infusions of bupivacaine via wound catheters in juvenile animals). Mepivacaine demonstrates significantly lower chondrotoxic potential than bupivacaine.